An evolution in the early diagnosis has been the discovery of novel AKI biomarkers, such as Cystatin C (9), neutrophil gelatinase-associated lipocalin (NGAL) (10, 11), kidney injury molecule 1 (12), and soluble urokinase plasminogen activator receptor (suPAR) (13). The gene discussed is LCN2; the disease is acute kidney injury.